ADC Series (VI) ADC Combination Therapy : Why Antibody–Drug Conjugates Often Need Strategic Partnerships
- Jason Lu
- Mar 7
- 4 min read
Executive Summary
Over the past decade, antibody–drug conjugates (ADCs) have emerged as one of the most promising platforms in oncology drug development. However, even clinically successful ADCs rarely maintain long-term tumor control when used as single agents.
The reason is not simply insufficient drug potency. Tumors possess remarkable adaptive capacity and can gradually evade ADC-mediated cytotoxicity through mechanisms such as antigen downregulation, altered internalization, or activation of DNA repair pathways.
As a result, increasing attention is being directed toward ADC combination therapy—the integration of ADCs with other therapeutic modalities such as immunotherapy, targeted small molecules, or DNA repair inhibitors.
This article explores:
Why single-agent ADC therapy often has limited durability
The mechanistic rationale for combining ADCs with immunotherapy
Potential synergy with DNA repair inhibitors
The emerging role of multispecific ADCs
The evolving clinical trial landscape of ADC combinations
Understanding these dynamics helps shift the perspective from single drug development to platform-level therapeutic strategy.
1. Why Single-Agent ADC Therapy Has Limits
As discussed in the previous article on ADC resistance, tumors can develop multiple mechanisms to reduce ADC effectiveness over time.
Common resistance pathways include:
Target downregulation
Altered receptor internalization
Changes in lysosomal trafficking
Efflux pumps exporting cytotoxic payloads
Activation of DNA repair pathways
Importantly, tumors do not need to completely block ADC activity. Even modest reductions in intracellular payload exposure can allow resistant cell populations to emerge.
This evolutionary pressure explains why researchers increasingly explore strategies that apply multiple simultaneous stresses on tumor survival pathways.
This concept forms the biological foundation of ADC combination therapy.
2. Mechanistic Rationale for ADC and Immunotherapy
Some ADC payloads can induce tumor cell death in ways that stimulate immune recognition.
In certain contexts, tumor cell destruction may lead to immunogenic cell death (ICD).
ICD is characterized by several biological events:
Release of tumor antigens
Exposure of danger-associated molecular patterns (DAMPs)
Activation of dendritic cells
These events can promote:
antigen presentation
T-cell priming
enhanced anti-tumor immune responses
Because immune checkpoint inhibitors work by reactivating T-cells, combining ADCs with PD-1 or PD-L1 inhibitorsprovides a compelling biological rationale.
Consequently, multiple ongoing clinical trials are exploring these combinations across tumor types.
3. ADCs Combined with DNA Repair Inhibitors
Many ADC payloads exert cytotoxic effects by inducing DNA damage.
Examples include payload classes such as:
Topoisomerase I inhibitors
DNA cross-linking agents
Tumor cells often rely on DNA repair mechanisms to survive these insults. Blocking repair pathways may therefore amplify ADC-induced cytotoxicity.
This concept has led researchers to investigate combinations such as:
ADC + PARP inhibitors
ADC + ATR inhibitors
In this strategy, the ADC generates DNA damage while the repair inhibitor prevents the tumor cell from correcting the damage.
However, this approach introduces additional challenges. Both ADCs and DNA repair inhibitors may produce hematologic toxicity, which requires careful dose optimization in clinical trials.
4. ADCs Combined with Targeted Small Molecules
Another emerging approach involves targeting tumor survival signaling pathways.
Many cancers depend on pathways such as:
PI3K signaling
MAPK signaling
cell cycle regulators
Inhibiting these pathways may reduce the tumor cell’s ability to tolerate cytotoxic stress induced by ADC payloads.
Additionally, targeted therapies can alter cellular processes including:
cell cycle progression
apoptosis thresholds
DNA repair activity
These biological changes may enhance ADC sensitivity.
As a result, combinations of ADCs with targeted small-molecule inhibitors are being actively explored in both preclinical and clinical settings.
5. Multispecific ADCs and Combination Strategies
Another rapidly evolving direction in the ADC field is the development of multispecific ADCs.
Traditional ADCs recognize a single tumor antigen such as HER2 or Trop-2. However, tumor heterogeneity often limits the durability of single-target approaches.
Multispecific ADCs aim to address this challenge through designs such as:
bispecific ADCs
dual-target ADCs
By recognizing two tumor antigens simultaneously, these molecules may improve tumor selectivity and reduce resistance driven by antigen loss.
Multispecific ADCs may also interact synergistically with combination therapy strategies by:
improving tumor targeting
increasing internalization efficiency
enhancing antigen presentation
However, these designs introduce additional challenges related to molecular engineering, pharmacokinetics, and manufacturing complexity.
6. The Clinical Trial Landscape of ADC Combination Therapy
ADC combination therapy is rapidly expanding within the clinical trial ecosystem.
Across multiple cancer types—including breast cancer, lung cancer, gastric cancer, and urothelial carcinoma—numerous studies are investigating ADC combinations with other therapies.
Common clinical strategies include:
ADC + Immune Checkpoint Inhibitors
This approach leverages both direct cytotoxicity from the ADC and immune activation from checkpoint blockade.
ADC + Chemotherapy
Traditional chemotherapy combinations may increase tumor stress, though careful toxicity management is required.
ADC + Targeted Therapy
Trials are exploring combinations with agents such as:
PARP inhibitors
CDK inhibitors
PI3K inhibitors
These strategies aim to interfere with tumor survival pathways and delay resistance development.
However, designing successful combination trials requires careful consideration of several factors:
Overlapping toxicity
Dose optimization
Biomarker-guided patient selection
For these reasons, the future of ADC combination therapy is closely linked to precision oncology approaches.
From Mechanism to Strategy | LuTra Studio Consulting
ADC combination therapy is not only a clinical decision—it is fundamentally a platform strategy question.
Early development decisions influence whether an ADC program can successfully integrate with combination therapies.
Key considerations include:
Target durability and expression patterns
Payload mechanism of action
Potential toxicity interactions
Clinical development pathways
At LuTra Studio, we support teams in integrating biological insight, drug engineering, and clinical strategy to design ADC platforms with long-term scalability.
Successful ADC programs are not defined solely by early response rates, but by their ability to adapt within evolving therapeutic ecosystems.
References
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N.
Strategies and challenges for the next generation of antibody–drug conjugates.
Nature Reviews Drug Discovery, 2017.
Drago, J. Z., Modi, S., & Chandarlapaty, S.
Unlocking the potential of antibody–drug conjugates for cancer therapy.
Nature Reviews Clinical Oncology, 2021.
Loganzo, F., Sung, M., & Gerber, H. P.
Mechanisms of resistance to antibody–drug conjugates.
Molecular Cancer Therapeutics, 2016.
Comments